NCT03016312
Disease Type: Genitourinary
Status: Open
Trial Information
A Phase III Multicenter, randomized, placebo controlled double blind study of Atezolizumab in combination with Enzalutamide versus Enzalutamide alone in patients with metastatic CRPC after failure of an androgen synthesis inhibitor and failure of, ineligibility for, or refusal of a taxane regimen
Click here for more information
This trial is available at:
Methodist Estabrook Cancer Center
8303 Dodge Street, Suite 250, Omaha, NE 68114
Phone: 402-354-8124
Fax: 402-354-8127
Midwest Cancer Center – Legacy
17201 Wright Street, Suite 200, Omaha, NE 68130
Phone: 402-334-4773
Fax: 402-330-7463
Midwest Cancer Center – Papillion
611 Fenwick Drive, Papillion, NE 68046
Phone: 402-593-3141
Fax: 402-593-3145
For more information, please contact: